Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyranosyl lipid adjuvant - Revelation Biosciences

Drug Profile

Glycopyranosyl lipid adjuvant - Revelation Biosciences

Alternative Names: Gemini - Revelation Biosciences; GLA - Revelation Biosciences; Glucopyranosyl Lipid A - Revelation Biosciences; PHAD - Revelation Biosciences; Phosphorylated hexaacylated disaccharide - Revelation Biosciences; REVTx 200 - Revelation Biosciences; REVTx 99; REVTx-100; REVTx-200; REVTx-300; REVTx-99a; REVTx-99b; Synthetic monophosphoryl Lipid A - Revelation Biosciences

Latest Information Update: 27 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Revelation Biosciences
  • Class Adjuvants; Anti-infectives; Antiallergics; Antineoplastics; Antivirals; Hepatoprotectants; Urologics
  • Mechanism of Action Toll-like receptor 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H3N2 subtype
  • Phase I Allergic rhinitis; Nasal congestion; Unspecified
  • Preclinical Acute kidney injury; COVID 2019 infections; Infections; Influenza virus infections; Non-alcoholic steatohepatitis; Postoperative infections; Renal failure
  • No development reported Respiratory tract infections; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 24 Jun 2024 Adverse events data from a phase I trial in Healthy volunteers were released by Revelation Biosciences
  • 24 Jun 2024 Revelation Biosciences plans a phase Ib trial for Acute kidney injury (Prevention) in 2024
  • 13 Jun 2024 Revelation Biosciences completes enrolment in a phase-I clinical trials in Unspecified (In volunteers, In adults) in Australia (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top